In situ cancer vaccination using lipidoid nanoparticles

Jinjin Chen,Min Qiu,Zhongfeng Ye,Thomas Nyalile,Yamin Li,Zachary Glass,Xuewei Zhao,Liu Yang,Jianzhu Chen,Qiaobing Xu

DOI: https://doi.org/10.1126/sciadv.abf1244

IF: 13.6

2021-05-07

Science Advances

Abstract:In situ cancer vaccination by lipidoid nanoparticles enhances antigen cross-presentation and STING activation.

multidisciplinary sciences

What problem does this paper attempt to address?

In Situ STING‐Activating Nanovaccination with TIGIT Blockade for Enhanced Immunotherapy of Anti‐PD‐1‐Resistant Tumors

Beibei Zhang,Juan Zhang,Yaqiong Li,Na Li,Yuzhou Wang,Ru Jang,Xiaoxia Xu,Ruifang Li,Zhenzhen Chen,Shaobo Duan,Yongchao Wang,Lianzhong Zhang

DOI: https://doi.org/10.1002/adma.202300171

IF: 29.4

2023-04-14

Advanced Materials

Abstract:Immunotherapies comprising programmed cell death protein 1/PD ligand 1 (PD‐1/PD‐L1) immune checkpoint inhibitors are effective cancer treatments. However, the low response rate and immunoresistance resulting from alternative immune checkpoint upregulation and inefficient immune stimulation by T cells are problematic. The present report describes a biomimetic nanoplatform that simultaneously blocks the alternative T cell immunoglobulin and immunoreceptor tyrosine‐based inhibitory motif domain (TIGIT) checkpoint and activates the stimulator of interferon genes (STING) signaling pathway in situ for enhanced antitumor immunity. The nanoplatform is engineered by fusing a red blood cell membrane with glutathione‐responsive liposome encapsulated cascade‐activating chemo‐agents (β‐lapachone and tirapazamine), and anchoring them with a detachable TIGIT block peptide (named as RTLT). In the tumor environment, the peptide was spatiotemporally released to reverse T‐cell exhaustion and restore antitumor immunity. The cascade activation of chemotherapeutic agents caused DNA damage and inhibited the repair of double‐stranded DNA, which induced robust in situ STING activation for an efficient immune response. The RTLT inhibited anti‐PD‐1‐resistant tumor growth, and prevented tumor metastasis and recurrence in vivo by inducing antigen‐specific immune memory. This biomimetic nanoplatform thus provides a promising strategy for in situ cancer vaccination. This article is protected by copyright. All rights reserved

materials science, multidisciplinary,chemistry, physical,physics, applied, condensed matter,nanoscience & nanotechnology
Hybrid nanoparticle–mediated simultaneous ROS scavenging and STING activation improve the antitumor immunity of in situ vaccines

Jianing Li,Tianze Wu,Weidong Wang,Yimin Gong,Mingzhu Lu,Mengmeng Zhang,Wanyue Lu,Yaming Zhou,Yannan Yang

DOI: https://doi.org/10.1126/sciadv.adn3002

IF: 13.6

2024-09-20

Science Advances

Abstract:In situ vaccine (ISV) is a versatile and personalized local immunotherapeutic strategy. However, the compromised viability and function of dendritic cells (DCs) in a tumor microenvironment (TME) largely limit the therapeutic efficacy. We designed a hybrid nanoparticle–based ISV, which accomplished superior cancer immunotherapy via simultaneously scavenging reactive oxygen species (ROS) and activating the stimulator of interferon genes (STING) pathway in DCs. This ISV was constructed by encapsulating a chemodrug, SN38, into diselenide bond–bridged organosilica nanoparticles, followed by coating with a Mn 2+ -based metal phenolic network. We show that this ISV can activate the STING pathway through Mn 2+ and SN38 comediated signaling and simultaneously scavenge preexisting H 2 O 2 in the TME and Mn 2+ -catalyzed •OH by leveraging the antioxidant property of diselenide and polyphenol. This ISV effectively activated DCs and protected them from oxidative damage, leading to remarkable downstream T cell activation and systemic antitumor immunity. This work highlights a nanoparticle design that manipulates DCs in the TME for improving the ISV.

multidisciplinary sciences
In situ activation of STING pathway with polymeric SN38 for cancer chemoimmunotherapy

Jiayu Zhao,Sheng Ma,Yudi Xu,Xinghui Si,Haochen Yao,Zichao Huang,Yu Zhang,Haiyang Yu,Zhaohui Tang,Wantong Song,Xuesi Chen

DOI: https://doi.org/10.1016/j.biomaterials.2020.120542

IF: 14

2021-01-01

Biomaterials

Abstract:STING (stimulator of interferon genes) signaling pathway has attracted considerable attention in cancer immunotherapy due to its capacity to boost vigorous antitumor immunity. However, the shortage of effective STING agonists limits the promotion of STING pathway in cancer treatment. Herein, we present an approach for in situ activation of STING pathway with nanoparticles delivered DNA-targeting chemo agents, based on the understanding that cytosol DNA is a pre-requisite for STING pathway activation. Through in vitro screening among several DNA-targeting chemo agents, we identified 7-ethyl-10-hydroxycamptothecin (SN38) as the most potent drug for stimulating interferon (IFN)-β secretion and proved that this process is mediated by the passage of DNA-containing exosomes from treated tumor cells to bone marrow-derived dendritic cells (BMDCs) and subsequent activation of the STING pathway. Furthermore, we designed a polymeric-SN38 conjugate that could self-assemble into nanoparticles (SN38-NPs) for in vivo application. The SN38-NPs formulation reduced toxicity of free SN38, effectively stimulated the activation of STING pathway in E0771 tumors, and resulted in a tumor suppression rate (TSR%) of 82.6%. Our results revealed a new mechanism of SN38 in cancer treatment and should inspire using more DNA-targeting agents, especially in nanoformulation, for activating STING pathway and cancer chemoimmunotherapy.

engineering, biomedical,materials science, biomaterials
Acid‐Ionizable Iron Nanoadjuvant Augments STING Activation for Personalized Vaccination Immunotherapy of Cancer

Fangmin Chen,Tianliang Li,Huijuan Zhang,Madiha Saeed,Xiaoying Liu,Lujia Huang,Xiyuan Wang,Jing Gao,Bo Hou,Yi Lai,Chunyong Ding,Zhiai Xu,Zuoquan Xie,Min Luo,Haijun Yu

DOI: https://doi.org/10.1002/adma.202209910

IF: 29.4

2022-12-30

Advanced Materials

Abstract:The critical challenge for cancer vaccine‐induced T‐cell immunity is the sustained activation of antigen cross‐presentation in antigen‐presenting cells (APCs) with innate immune stimulation. In this study, we first discover that the clinically used magnetic contrast agents, iron oxide nanoparticles (IONPs), markedly augment the type‐I interferon (IFN‐I) production profile of the STING agonist MSA‐2, and achieve a 16‐fold dosage‐sparing effect in the human STING haplotype. We next co‐assembled acid‐ionizable copolymers with IONPs and MSA‐2 into iron nanoadjuvants to concentrate STING activation in the draining lymph nodes. The top candidate iron nanoadjuvant (PEIM) efficiently delivers the model antigen ovalbumin (OVA) to CD169+ APCs and facilitates antigen cross‐presentation to elicit a 55‐fold greater frequency of antigen‐specific CD8+ cytotoxic T‐lymphocyte response than soluble antigen. PEIM@OVA nanovaccine immunization induces potent and durable antitumor immunity to prevent tumor lung metastasis and eliminate established tumors. Moreover, PEIM nanoadjuvant is applicable to deliver autologous tumor antigen and synergizes with immune checkpoint blockade therapy for prevention of postoperative tumor recurrence and distant metastasis in B16‐OVA melanoma and MC38 colorectal tumor models. The acid‐ionizable iron nanoadjuvant offers a generalizable and readily translatable strategy to augment STING cascade activation and antigen cross‐presentation for personalized cancer vaccination immunotherapy. This article is protected by copyright. All rights reserved

materials science, multidisciplinary,chemistry, physical,physics, applied, condensed matter,nanoscience & nanotechnology
A STING-activating nanovaccine for cancer immunotherapy

Min Luo,Hua Wang,Zhaohui Wang,Haocheng Cai,Zhigang Lu,Yang Li,Mingjian Du,Gang Huang,Chensu Wang,Xiang Chen,Matthew R. Porembka,Jayanthi Lea,Arthur E. Frankel,Yang-Xin Fu,Zhijian J. Chen,Jinming Gao

DOI: https://doi.org/10.1038/nnano.2017.52

IF: 38.3

2017-04-24

Nature Nanotechnology

Abstract:STING-activating nanoparticle vaccines achieve robust activation of tumour-specific T cells for cancer immunotherapy.

materials science, multidisciplinary,nanoscience & nanotechnology
In Situ Cocktail Nanovaccine for Cancer Immunotherapy

Mohan Liu,Daoyuan Xie,Die Hu,Rui Zhang,Yusi Wang,Lin Tang,Bailing Zhou,Binyan Zhao,Li Yang

DOI: https://doi.org/10.1002/advs.202207697

IF: 15.1

2023-09-23

Advanced Science

Abstract:An in situ nanovaccine based on a cationic peptide with cholesterol‐modified, DP7‐C, for cancer immunotherapy is rationally designed, and develop a cancer nanovaccine that is easy to preparate. The nanovaccine includes cocktail small interfering RNAs (siRNAs) and immunologic adjuvant CpG ODNs, has synergistic effect in the cancer treatment. This versatile methodology provides an alternative approach for developing cancer nanovaccines. In situ vaccination is a desirable strategy for cancer immunotherapy due to its convenience and capacity to target tumor antigens. Here, an in situ nanovaccine based on a cationic peptide with cholesterol‐modified, DP7‐C, for cancer immunotherapy is rationally designed, and developed a cancer nanovaccine that is easy to preparate. The nanovaccine includes cocktail small interfering RNAs (siRNAs) and immunologic adjuvant CpG ODNs, has synergistic effect in the cancer treatment. This nanovaccine can induce tumor cell death, promote antigen presentation and relieve immune suppression in the tumor microenvironment (TME). Moreover, this nanovaccine is administered to CT26 (hot) and B16F10 (cold) tumor model mice, in which it targeted the primary tumors and induced systemic antitumor immunity to inhibit metastasis. It is validated that the nanovaccine can convert cold tumors into hot tumors. Furthermore, the nanovaccine increased the immune response to anti‐PD‐1 therapy by modulating the TME in both CT26‐ and B16F10‐tumor‐bearing mice. The siRNA cocktail/CpG ODN/self‐assembling peptide nanovaccine is a simple and universal tool that can effectively generate specific tumor cell antigens and can be combined with immuno‐oncology agents to enhance antitumor immune activity. The versatile methodology provides an alternative approach for developing cancer nanovaccines.

materials science, multidisciplinary,nanoscience & nanotechnology,chemistry
A Bi-Adjuvant Nanovaccine Amplifying STING Activation for Cancer Immunotherapy

Dan Liu,Shuang Liang,Kongshuo Ma,Kaiqing Yun,Mengli Zhou,Jianjun Yao,Linna Hai,Yuxuan Peng,Zhaohui Wang

DOI: https://doi.org/10.1016/j.nantod.2024.102372

IF: 17.4

2024-01-01

Nano Today

Abstract:The insufficient immune activation and immunosuppressive microenvironment restrict the therapeutic efficacy of cancer vaccines. Herein, we exploited a bi-adjuvant nanovaccine to amplify the activation of the stimulator of interferon genes (STING) for potent and durable anti-tumor immunity. STING agonist (MnO2 nanoparticles), tolllike receptor 9 agonist (CpG), and antigenic proteins or peptides were strategically formulated into nanovaccines (MnC NVs) by a one-step biomineralization method. The nanovaccine efficiently targeted dendritic cells of draining lymph nodes, in which CpG-mediated the stimulation of nuclear factor-kappa B pathway augmented STING signaling. RNA sequencing analysis validated the enhanced expression of relevant genes of type-I interferon signaling pathways. The priming of antigen-specific CD8+ T cells and humoral immune responses led to potent tumor growth inhibition and prolonged survival time in melanoma and human papilloma virus-derived tumor models. MnC NVs were able to synergize with immune checkpoint blockade therapy, with 80 % survival over 40 days in TC-1 tumor model. Moreover, rechallenging of tumor-free mice with homotypic cells resulted in complete tumor growth inhibition, suggesting the generation of a long-term memory effect. The simplified nanovaccine platform provides a safe and robust strategy to boost STING-mediated anti-tumor immunity for personalized cancer immunotherapy, showing significant potential for clinical translation.
pH‐Responsive STING‐Activating DNA Nanovaccines for Cancer Immunotherapy

Yu Zhang,Tingting Shen,Shurong Zhou,Weinan Wang,Shuibin Lin,Guizhi Zhu

DOI: https://doi.org/10.1002/adtp.202000083

IF: 5.003

2020-06-08

Advanced Therapeutics

Abstract:Cyclic dinucleotides (CDNs), such as c-di-GMP (CDG), are agonists for stimulator of interferon genes (STING) and are promising for cancer immunotherapy. Yet, the therapeutic efficacy of CDNs has been limited by poor delivery and biostability. Here, STING-activating DNA nanovaccines (STING-NVs) are developed, which biostabilize, deliver, and conditionally release CDG in the endosome of immune cells, elicit potent antitumor immune responses in murine and human immune cells, ameliorate immunosuppression in vitro and in the tumor microenvironment, and mediate potent cancer immunotherapy in a murine melanoma model. STING-NVs have PLA-b-PEG in the core and cytosine (C)-rich i-motif DNA on the surface. i-Motif DNA undergoes characteristic pH-responsive conformational switch, allowing efficient CDG loading via C:G base pairing at physiological pH, and CDG release in sensitive response to acidic environment such as cell endosome. STING-NVs protect CDG from enzymatic degradation. STING-NVs facilitate cell delivery. Remarkably, STING-NVs promote the endosome escape of CDG by ninefold, and potentiate antitumor immunity. STING-NVs repolarize immunosuppressive M2-like macrophages into antitumor M1-like macrophages in vitro and in the tumor microenvironment of melanoma. In a poorly immunogenic murine melanoma model, intralesional STING-NVs outperform liposomal CDG and fluoride-CDG for melanoma immunotherapy. These results suggest the great potential of STING-NVs for cancer immunotherapy.
Enhanced systemic tumor suppression by in situ vaccine combining radiation and OX40 agonist with CpG therapy

Zhichen Sun,Yanhong Chu,Jie Xiao,Yueling Yang,Fanyan Meng,Xinyue Wang,Yanbing Dong,Junmeng Zhu,Yirong Wu,Lanqun Qin,Yaohua Ke,Baorui Liu,Qin Liu

DOI: https://doi.org/10.1186/s12967-023-04504-w

IF: 8.44

2023-09-14

Journal of Translational Medicine

Abstract:In situ tumor vaccine has been gradually becoming a hot research field for its advantage of achieving personalized tumor therapy without prior antigen identification. Various in situ tumor vaccine regimens have been reported to exert considerable antitumor efficacy in preclinical and clinical studies. However, the design of in situ tumor vaccines still needs further optimization and the underlying immune mechanism also waits for deeper investigation.

medicine, research & experimental
Intradermal vaccination with a phytoglycogen nanoparticle and STING agonist induces cytotoxic T lymphocyte-mediated antitumor immunity

Juan F. Hernandez-Franco,Imran M. Jan,Bennett D. Elzey,Harm HogenEsch

DOI: https://doi.org/10.1038/s41541-024-00943-8

2024-08-18

npj Vaccines

Abstract:A critical aspect of cancer vaccine development is the formulation with effective adjuvants. This study evaluated whether combining a cationic plant-derived nanoparticle adjuvant (Nano-11) with the clinically tested STING agonist ADU-S100 (MIW815) could stimulate anticancer immunity by intradermal vaccination. Nano-11 combined with ADU-S100 (NanoST) synergistically activated antigen-presenting cells, facilitating protein antigen cross-presentation in vitro and in vivo. Intradermal vaccination using ovalbumin (OVA) as a tumor antigen and combined with Nano-11 or NanoST prevented the development of murine B16-OVA melanoma and E.G7-OVA lymphoma tumors. The antitumor immunity was abolished by CD8 + T cell depletion but not by CD4 + T cell depletion. Therapeutic vaccination with NanoST increased mouse survival by inhibiting B16-OVA tumor growth, and this effect was further enhanced by PD-1 checkpoint blockade. Our study provides a strong rationale for developing NanoST as an adjuvant for intradermal vaccination and next-generation preventative and therapeutic cancer vaccines by STING-targeted activation.

immunology,medicine, research & experimental
Lipid-based Nanoparticles As Drug Delivery Systems for Cancer Immunotherapy.

Yang Hao,Zhonghao Ji,Hengzong Zhou,Dongrun Wu,Zili Gu,Dongxu Wang,Peter Ten Dijke

DOI: https://doi.org/10.1002/mco2.339

2023-01-01

MedComm

Abstract:Immune checkpoint inhibitors (ICIs) have shown remarkable success in cancer treatment. However, in cancer patients without sufficient antitumor immunity, numerous data indicate that blocking the negative signals elicited by immune checkpoints is ineffective. Drugs that stimulate immune activation-related pathways are emerging as another route for improving immunotherapy. In addition, the development of nanotechnology presents a promising platform for tissue and cell type-specific delivery and improved uptake of immunomodulatory agents, ultimately leading to enhanced cancer immunotherapy and reduced side effects. In this review, we summarize and discuss the latest developments in nanoparticles (NPs) for cancer immuno-oncology therapy with a focus on lipid-based NPs (lipid-NPs), including the characteristics and advantages of various types. Using the agonists targeting stimulation of the interferon genes (STING) transmembrane protein as an exemplar, we review the potential of various lipid-NPs to augment STING agonist therapy. Furthermore, we present recent findings and underlying mechanisms on how STING pathway activation fosters antitumor immunity and regulates the tumor microenvironment and provide a summary of the distinct STING agonists in preclinical studies and clinical trials. Ultimately, we conduct a critical assessment of the obstacles and future directions in the utilization of lipid-NPs to enhance cancer immunotherapy.
Abstract 5761: A nanoplatform based on an in situ tumor vaccine and activation of STING and TLR7/8 pathways for enhanced NSCLC immunotherapy

Haiyu Zhou,Hengliang Hou,Bin Xu,Yucheng Huang,Hongrui Qiu

DOI: https://doi.org/10.1158/1538-7445.am2024-5761

IF: 11.2

2024-03-31

Cancer Research

Abstract:Background: Immunotherapy has emerged as a promising treatment for tumors following surgical, radiotherapy, and chemotherapy interventions. Therapeutic tumor vaccines are considered highly effective in eliminating tumors and preventing their recurrence and metastasis due to their ability to induce or enhance T cell-mediated immune responses. However, the therapeutic efficacy of these vaccines is impeded by the heterogeneity present both between and within tumors. In contrast, in situ tumor vaccines, prepared from autologous antigens in tumor patients, present another promising strategy for generating comprehensive immune responses. Methods: In this study, we designed a multifunctional nanopolymer, the transformable nanoassembly PEG-Ce6@PAEMA/R848. This assembly includes the photosensitizer polyethylene glycol-chlorin-e6 (PEG-Ce6), the tumor pH-sensitive polymer poly(2-azepane ethyl methacrylate) (PAEMA), and the immune adjuvant Resiquimod (R-848). The objective is to confirm the activation of bone marrow-derived dendritic cells (DCs) at the cellular level. Subsequently, we investigated the maturation of DCs in lymph nodes and tumor sites in vivo. Results: In the particle characterization process, successful synthesis of nanoparticles was achieved, along with the verification of their acid-responsive function and toxic effects. Furthermore, in vitro experiments demonstrated the activation of bone marrow-derived dendritic cells (DCs) (Figure 1).To further investigate the in vivo vaccine effects, C57BL/6 mice were euthanized, and lymph nodes were extracted to examine the accumulation of FITC-PAEMA. It can be observed that, due to the reduction in size of the particles in the tumor acidic environment, the immune adjuvant can easily enter the lymph nodes. Activation of the STING pathway in dendritic cells within the lymph nodes was detected through qPCR. The maturation of dendritic cells (DCs) in the lymph nodes was determined using flow cytometry (Figure 2). Conclusions: In this study, we developed a straightforward yet potent strategy focused on in situ tumor targeting. This approach effectively inhibits tumor growth while inducing immunogenic cell death and eliciting a systemic anti-tumor immune response against cancer cells. Additionally, we intend to validate the therapeutic efficacy of this strategy on metastatic and distal tumors in subsequent investigations. Citation Format: Haiyu Zhou, Hengliang Hou, Bin Xu, Yucheng Huang, Hongrui Qiu. A nanoplatform based on an in situ tumor vaccine and activation of STING and TLR7/8 pathways for enhanced NSCLC immunotherapy [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 5761.

oncology
Robust and Sustained STING Pathway Activation via Hydrogel-Based In Situ Vaccination for Cancer Immunotherapy

Sheng-Liang Cheng,Hsin-Mei Lee,Chung-Pin Li,Mei-Wei Lin,Min-Yuan Chou,Yu-Ting Yen,Tun-Han Wu,Yun-Chen Lian,Yu-Chuan Shih,Chi-Shiun Chiang,Ting-Wen Chen,Dehui Wan,Yunching Chen

DOI: https://doi.org/10.1021/acsnano.3c12337

IF: 17.1

2024-10-17

ACS Nano

Abstract:The stimulator of interferon genes (STING) pathway is crucial for tumor immunity, leading to the exploration of STING agonists as potential immunotherapy adjuvants. However, their clinical application faces obstacles including poor pharmacokinetics, transient activation, and an immunosuppressive tumor microenvironment (TME). Addressing these limitations, our study aims to develop an injectable silk fibroin hydrogel-based in situ vaccine. It incorporates a nanoscale STING agonist, an immunogenic...

materials science, multidisciplinary,chemistry, physical,nanoscience & nanotechnology
Antigen‐Capturing Dendritic‐Cell‐Targeting Nanoparticles for Enhanced Tumor Immunotherapy Based on Photothermal‐Therapy‐Induced in‐situ Vaccination

Yingmin Li,Yang Luo,Lamei Hou,Zhengjie Huang,Yi Wang,Shaobing Zhou

DOI: https://doi.org/10.1002/adhm.202202871

IF: 10

2023-06-06

Advanced Healthcare Materials

Abstract:In‐situ vaccines have revolutionized immunotherapy as they can stimulate tumor‐specific immune responses, with the cancer being the antigen source. However, the heterogeneity of tumor antigens and insufficient dendritic cell (DC) activation result in low cancer immunogenicity and hence poor vaccine response. Here, we designed a new in‐situ vaccine composed of acid‐responsive liposome‐coated polydopamine (PDA) nanoparticles modified with mannose and loaded with resiquimod (R848) to promote the efficacy of immunotherapy. The in‐situ vaccine can actively target the tumor site based on the decomposition of the liposome, while the PDA nanoparticles promote photothermal therapy and capture the immunogenic cell‐death‐induced tumor‐associated antigens based on the adsorption effect of dopamine‐mimetic mussels. The PDA nanoparticles, which were modified with a mannose ligand, target the DCs and release R848 for activated antigen presentation. As a result, the in‐situ vaccine not only effectively activates the maturation of the DCs but also significantly enhances their effect on cytotoxic T lymphocyte cells. Furthermore, the vaccine effectively inhibits the distant recurrence and metastasis of tumors via long‐term immune memory effects. Therefore, the in‐situ vaccine provides a potential strategy for improving the efficacy of cancer immunotherapy. This article is protected by copyright. All rights reserved

nanoscience & nanotechnology,engineering, biomedical,materials science, biomaterials
STING Activator c-di-GMP-Loaded Mesoporous Silica Nanoparticles Enhance Immunotherapy Against Breast Cancer

Yi-Ping Chen,Li Xu,Tao-Wei Tang,Cheuh-Hsuan Chen,Quan-Hong Zheng,Tsang-Pai Liu,Chung-Yuan Mou,Cheng-Hsun Wu,Si-Han Wu

DOI: https://doi.org/10.1021/acsami.0c16728

2020-12-11

Abstract:Reversing the immunosuppressive tumor microenvironment (TME) is a strategic initiative to sensitize cancer immunotherapy. Emerging evidence shows that cyclic diguanylate monophosphate (c-di-GMP or cdG) can induce the stimulator of interferon genes (STING) pathway activation of antigen-presenting cells (APCs) and upregulate expression of type I interferons (IFNs) to enhance tumor immunogenicity. In vitro anionic cdG revealed fast plasma clearance, poor membrane permeability, and inadequate cytosolic bioavailability. Therefore, we explored a comprehensive "in situ vaccination" strategy on the basis of nanomedicine to trigger robust antitumor immunity. Rhodamine B isothiocyanate (RITC) fluorescent mesoporous silica nanoparticles (MSN) synthesized and modified with poly(ethylene glycol) (PEG) and an ammonium-based cationic molecule (TA) were loaded with negatively charged cdG via electrostatic interactions to form Treatment of RAW 264.7 cells with markedly stimulated the secretion of IL-6, IL-1β, and IFN-β along with phospho-STING (Ser365) protein expression. In vivo enhanced infiltration of leukocytes, including CD11c+ dendritic cells, F4/80+ macrophages, CD4+ T cells, and CD8+ T cells within the tumor microenvironment (TME), resulting in dramatic tumor growth inhibition in 4T1 breast tumor-bearing Balb/c mice. Our findings suggest that a nanobased platform can overcome the obstacles bare cdG can face in the TME. Our approach of an in situ vaccination using a STING agonist provides an attractive immunotherapy-based strategy for treating breast cancer.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acsami.0c16728?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acsami.0c16728</a>.Particle size distribution of RMSN-PEG-TA; X-ray diffraction patterns of RMSN-PEG-TA and of RMSN; cell viability assay; immunohistochemistry staining images; and flow cytometric analysis (<a class="ext-link" href="/doi/suppl/10.1021/acsami.0c16728/suppl_file/am0c16728_si_001.pdf">PDF</a>)This article has not yet been cited by other publications.

materials science, multidisciplinary,nanoscience & nanotechnology
Intravenous Delivery of STING Agonists Using Acid-Sensitive Polycationic Polymer-Modified Lipid Nanoparticles for Enhanced Tumor Immunotherapy

Ying He,Ke Zheng,Xifeng Qin,Siyu Wang,Xuejing Li,Huiwen Liu,Mingyang Liu,Ruizhe Xu,Shaojun Peng,Zhiqing Pang

DOI: https://doi.org/10.1016/j.apsb.2024.06.004

IF: 14.903

2024-01-01

Acta Pharmaceutica Sinica B

Abstract:Although cancer immunotherapy has made great strides in the clinic, it is still hindered by the tumor immunosuppressive microenvironment (TIME). The stimulator of interferon genes (STING) pathway which can modulate TIME effectively has emerged as a promising therapeutic recently. However, the delivery of most STING agonists, specifically cyclic dinucleotides (CDNs), is performed intratumorally due to their insufficient pharmacological properties, such as weak permeability across cell membranes and vulnerability to nuclease degradation. To expand the clinical applicability of CDNs, a novel pH-sensitive polycationic polymer-modified lipid nanoparticle (LNP-B) system was developed for intravenous delivery of CDNs. LNP-B significantly extended the circulation of CDNs and enhanced the accumulation of CDNs within the tumor, spleen, and tumor-draining lymph nodes compared with free CDNs thereby triggering the STING pathway of dendritic cells and repolarizing pro-tumor macrophages. These events subsequently gave rise to potent anti-tumor immune reactions and substantial inhibition of tumors in CT26 colon cancer-bearing mouse models. In addition, due to the acid-sensitive property of the polycationic polymer, the delivery system of LNP-B was more biocompatible and safer compared with lipid nanoparticles formulated with an indissociable cationic DOTAP (LNP-D). These findings suggest that LNP-B has great potential in the intravenous delivery of CDNs for tumor immunotherapy.
Self-Assembled STING-Activating Coordination Nanoparticles for Cancer Immunotherapy and Vaccine Applications

Xiaoqi Sun,Xuehui Huang,Kyung Soo Park,Xingwu Zhou,Andrew A. Kennedy,Carla D. Pretto,Qi Wu,Ziye Wan,Yao Xu,Wang Gong,Jonathan Z. Sexton,Andrew W. Tai,Yu Leo Lei,James J. Moon

DOI: https://doi.org/10.1021/acsnano.3c11374

IF: 17.1

2024-04-05

ACS Nano

Abstract:The cGAS-STING pathway plays a crucial role in innate immune activation against cancer and infections, and STING agonists based on cyclic dinucleotides (CDN) have garnered attention for their potential use in cancer immunotherapy and vaccines. However, the limited drug-like properties of CDN necessitate an efficient delivery system to the immune system. To address these challenges, we developed an immunostimulatory delivery system for STING agonists. Here, we have examined aqueous coordination...

materials science, multidisciplinary,chemistry, physical,nanoscience & nanotechnology
In Situ Vaccination with An Injectable Nucleic Acid Hydrogel for Synergistic Cancer Immunotherapy

Fujun Wang,Miao Xie,Yangyang Huang,Yuhe Liu,Xinlong Liu,Lijuan Zhu,Xinyuan Zhu,Yuanyuan Guo,Chuan Zhang

DOI: https://doi.org/10.1002/anie.202315282

2024-01-22

Abstract:Recently, therapeutic cancer vaccines have emerged as promising candidates for cancer immunotherapy. Nevertheless, their efficacies are frequently impeded by challenges including inadequate antigen encapsulation, insufficient immune activation, and immunosuppressive tumor microenvironment. Herein, we report a three-in-one hydrogel assembled by nucleic acids (NAs) that can serve as a vaccine to in situ trigger strong immune response against cancer. Through site-specifically grafting the chemodrug, 7-ethyl-10-hydroxycamptothecin (also known as SN38), onto three component phosphorothioate (PS) DNA strands, a Y-shaped motif (Y-motif) with sticky ends is self-assembled, at one terminus of which an unmethylated cytosine-phosphate-guanine (CpG) segment is introduced as an immune agonist. Thereafter, programmed cell death ligand-1 (PD-L1) siRNA that performs as immune checkpoint inhibitor is designed as a crosslinker to assemble with the CpG- and SN38-containing Y-motif, resulting in the formation of final NA hydrogel vaccine. With three functional agents inside, the hydrogel can remarkably induce the immunogenic cell death to enhance the antigen presentation, promoting the dendritic cell maturation and effector T lymphocyte infiltration, as well as relieving the immunosuppressive tumor environment. When inoculated twice at tumor sites, the vaccine demonstrates a substantial antitumor effect in melanoma mouse model, proving its potential as a general platform for synergistic cancer immunotherapy.
In Situ Tumor Vaccine for Lymph Nodes Delivery and Cancer Therapy Based on Small Size Nanoadjuvant

Huilin Zhang,Yiwei Zhang,Haili Hu,Wenqin Yang,Xue Xia,Lei Lei,Ruyi Lin,Jiamei Li,Yuan Li,Huile Gao

DOI: https://doi.org/10.1002/smll.202301041

IF: 13.3

Small

Abstract:Tumor vaccine is a promising cancer treatment modality, however, the convenient antigens loading in vivo and efficient delivery of vaccines to lymph nodes (LNs) still remain a formidable challenge. Herein, an in situ nanovaccine strategy targeting LNs to induce powerful antitumor immune responses by converting the primary tumor into whole-cell antigens and then delivering these antigens and nanoadjuvants simultaneously to LNs is proposed. The in situ nanovaccine is based on a hydrogel system, which loaded with doxorubicin (DOX) and nanoadjuvant CpG-P-ss-M. The gel system exhibits ROS-responsive release of DOX and CpG-P-ss-M, generating abundant in situ storage of whole-cell tumor antigens. CpG-P-ss-M adsorbs tumor antigens through the positive surface charge and achieves charge reversal, forming small-sized and negatively charged tumor vaccines in situ, which are then primed to LNs. Eventually, the tumor vaccine promotes antigens uptake by dendritic cells (DCs), maturation of DCs, and proliferation of T cells. Moreover, the vaccine combined with anti-CTLA4 antibody and losartan inhibits tumor growth by 50%, significantly increasing the percentage of splenic cytotoxic T cells (CTLs), and generating tumor-specific immune responses. Overall, the treatment effectively inhibits primary tumor growth and induces tumor-specific immune response. This study provides a scalable strategy for in situ tumor vaccination.
Interface-sensitized prodrug nanoaggregate as an effective in situ antitumor vaccine

Yaxin Zheng,Qi Li,Qiulin Xu,Qin Wang,Wenbin He,Xin Hu,Tingting Li,Yang Li

DOI: https://doi.org/10.1016/j.ejps.2021.105910

IF: 5.112

2021-09-01

European Journal of Pharmaceutical Sciences

Abstract:In situ antitumor vaccines have been widely explored as an effective strategy to inhibit tumor growth by stimulating antitumor immune responses. Herein, we reported a simple and effective in situ antitumor vaccine, which was prepared by co-assembling cationic lipids (DOTAP) with the disulfide bond-linked lipid-drug conjugates of camptothecin and resiquimod. The resulting vaccine had a rod-sharped morphology with nanoscale sizes (average hydrodynamic diameter of ∼163.7 nm) and positively-charged interfaces (zeta potential ∼ +36.2 mV). The interfacial cationization of nanoaggregate resulted in 1000 folds faster redox-responsive drug release than that of unmodified ones, which induced a much more potent in vivo antitumor immune by accelerating the glutathione-responsive drug release at the tumor site. Such cationic lipid-drug nanoaggregates displayed many benefits, such as high co-loading capacity, simple preparation process, and wide applicability, which would serve as a promising new approach to design effective in situ antitumor vaccines.

pharmacology & pharmacy

In situ cancer vaccination using lipidoid nanoparticles

In Situ STING‐Activating Nanovaccination with TIGIT Blockade for Enhanced Immunotherapy of Anti‐PD‐1‐Resistant Tumors

Hybrid nanoparticle–mediated simultaneous ROS scavenging and STING activation improve the antitumor immunity of in situ vaccines

In situ activation of STING pathway with polymeric SN38 for cancer chemoimmunotherapy

Acid‐Ionizable Iron Nanoadjuvant Augments STING Activation for Personalized Vaccination Immunotherapy of Cancer

A STING-activating nanovaccine for cancer immunotherapy

In Situ Cocktail Nanovaccine for Cancer Immunotherapy

A Bi-Adjuvant Nanovaccine Amplifying STING Activation for Cancer Immunotherapy

pH‐Responsive STING‐Activating DNA Nanovaccines for Cancer Immunotherapy

Enhanced systemic tumor suppression by in situ vaccine combining radiation and OX40 agonist with CpG therapy

Intradermal vaccination with a phytoglycogen nanoparticle and STING agonist induces cytotoxic T lymphocyte-mediated antitumor immunity

Lipid-based Nanoparticles As Drug Delivery Systems for Cancer Immunotherapy.

Abstract 5761: A nanoplatform based on an in situ tumor vaccine and activation of STING and TLR7/8 pathways for enhanced NSCLC immunotherapy

Robust and Sustained STING Pathway Activation via Hydrogel-Based In Situ Vaccination for Cancer Immunotherapy

Antigen‐Capturing Dendritic‐Cell‐Targeting Nanoparticles for Enhanced Tumor Immunotherapy Based on Photothermal‐Therapy‐Induced in‐situ Vaccination

STING Activator c-di-GMP-Loaded Mesoporous Silica Nanoparticles Enhance Immunotherapy Against Breast Cancer

Intravenous Delivery of STING Agonists Using Acid-Sensitive Polycationic Polymer-Modified Lipid Nanoparticles for Enhanced Tumor Immunotherapy

Self-Assembled STING-Activating Coordination Nanoparticles for Cancer Immunotherapy and Vaccine Applications

In Situ Vaccination with An Injectable Nucleic Acid Hydrogel for Synergistic Cancer Immunotherapy

In Situ Tumor Vaccine for Lymph Nodes Delivery and Cancer Therapy Based on Small Size Nanoadjuvant

Interface-sensitized prodrug nanoaggregate as an effective in situ antitumor vaccine